What is Nucala? Understanding the Biologic Medication Mepolizumab
•
4 min read
First approved in 2015 for severe eosinophilic asthma, the biologic medication Nucala (mepolizumab) targets the protein interleukin-5 (IL-5) to reduce eosinophil levels, thereby managing a range of inflammatory conditions. It is not a quick-relief treatment but an add-on maintenance therapy.
